Planet 13 Holdings Past Earnings Performance
Past criteria checks 0/6
Planet 13 Holdings's earnings have been declining at an average annual rate of -44.6%, while the Pharmaceuticals industry saw earnings growing at 10.8% annually. Revenues have been growing at an average rate of 12.6% per year.
Key information
-44.6%
Earnings growth rate
-35.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 12.6% |
| Return on equity | -47.1% |
| Net Margin | -73.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Planet 13 Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 102 | -74 | 51 | 0 |
| 31 Mar 24 | 96 | -71 | 50 | 0 |
| 31 Dec 23 | 99 | -74 | 51 | 0 |
| 30 Sep 23 | 100 | -106 | 56 | 0 |
| 30 Jun 23 | 101 | -67 | 55 | 0 |
| 31 Mar 23 | 104 | -64 | 55 | 0 |
| 31 Dec 22 | 105 | -60 | 56 | 0 |
| 30 Sep 22 | 110 | -20 | 58 | 0 |
| 30 Jun 22 | 117 | -17 | 68 | 0 |
| 31 Mar 22 | 121 | -21 | 73 | 0 |
| 31 Dec 21 | 119 | -22 | 69 | 0 |
| 30 Sep 21 | 110 | -34 | 61 | 0 |
| 30 Jun 21 | 100 | -31 | 46 | 0 |
| 31 Mar 21 | 78 | -30 | 34 | 0 |
| 31 Dec 20 | 70 | -25 | 33 | 0 |
| 30 Sep 20 | 67 | -8 | 31 | 0 |
| 30 Jun 20 | 61 | -10 | 32 | 0 |
| 31 Mar 20 | 67 | -7 | 33 | 0 |
| 31 Dec 19 | 64 | -12 | 34 | 0 |
| 30 Sep 19 | 55 | -7 | 29 | 0 |
| 30 Jun 19 | 44 | -6 | 23 | 0 |
| 31 Mar 19 | 31 | -12 | 19 | 0 |
| 31 Dec 18 | 21 | -11 | 14 | 0 |
| 30 Sep 18 | 16 | -9 | 9 | 0 |
| 30 Jun 18 | 14 | -8 | 6 | 0 |
| 31 Mar 18 | 11 | -1 | 4 | 0 |
| 31 Dec 17 | 9 | -1 | 3 | 0 |
| 31 Dec 16 | 2 | -2 | 1 | 0 |
Quality Earnings: Y7Q is currently unprofitable.
Growing Profit Margin: Y7Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Y7Q is unprofitable, and losses have increased over the past 5 years at a rate of 44.6% per year.
Accelerating Growth: Unable to compare Y7Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: Y7Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: Y7Q has a negative Return on Equity (-47.11%), as it is currently unprofitable.